[1]Maus CE,Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2005, 49(8): 3192-3197.[2]曹广云,肖和平,闫丽萍,等.三种注射用抗结核药物对结核分枝杆菌的耐药情况分析. 中国防痨杂志, 2010, 32(4): 227-230.[3]Alangaden GJ, Kreiswirth BN, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1998, 42(5): 1295-1297.[4]陆宇,王彬,郑梅琴,等. 应用Alamar Blue和MTT测定抗结核药物最低抑菌浓度的研究. 中国防痨杂志, 2007, 29(6): 499-501.[5]Palomino JC, Martin A, Camacho M, et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2002, 46(8): 2720-2722.[6]Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother, 1997, 41(5): 1004-1009.[7]World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization, 2008.[8]张宗德,邢爱英,刘忠泉,等. 噻唑蓝和刃天青法在一线抗结核药物药敏试验中的应用. 中华检验医学杂志, 2008, 31(9): 989-992.[9]Franzblau SG, Witzig RS, McLaughlin JC, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol, 1998, 36(2):362-366.[10]Sugawara I, Zhang J, Li C. Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin. Indian J Exp Biol, 2009, 47(6): 520-522.[11]Tudó G,Rey E, Borrell S, et al. Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barcelona. J Antimicrob Chemother, 2010, 65(11): 2341-2346.[12]Sirgel FA, Tait M, Warren RM, et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist, 2011,18(2):193-197.[13]中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年). 北京:人民卫生出版社,2010:5-61.[14]郭颖,许钦龙. 110株结核分枝杆菌二线药敏结果分析. 临床肺科杂志,2011,16(8): 1279-1280.[15]施旭东, 王雷. 卷曲霉素对结核分枝杆菌体外抑菌作用的研究. 江苏大学学报(医学版), 2004, 14(2): 100-102.[16]王雷,施旭东. 4种氨基甙类抗生素对结核分枝杆菌(MTB)的体外抑菌作用的研究. 实验与检验医学, 2009, 27(4): 367-368.[17]Via LE, Cho SN, Hwang S, et al. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol, 2010, 48(2): 402-411.[18]Juréen P, Angeby K, Sturegrd E, et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol, 2010, 48(5): 1853-1858.[19]Engstrom A, Perskvist N, Werngren J, et al. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2011, 66(6): 1247-1254.[20]常珊,付育红,李琦,等.结核分枝杆菌临床分离株对四种注射用抗结核药物耐药及交叉耐药分析.中国防痨杂志,2013,35(1):37-40. |